Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J A Wood

Showing results (1-10 of 193) with videos related to

Pageof 20
Sort By:
Science Translational Medicine|April 29, 2010
Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challengeMatthew J A Wood
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 10, 2013
To skip or not to skip: that is the question for duchenne muscular dystrophyMatthew J A Wood
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|September 21, 2011
Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriersSamira Lakhal, Matthew J A Wood
Nature Reviews. Drug Discovery|August 2, 2011
Targeting RNA to treat neuromuscular diseaseFrancesco Muntoni, Matthew J A Wood
Molecular Biology of the Cell|October 24, 2008
Localization of double-stranded small interfering RNA to cytoplasmic processing bodies is Ago2 dependent and results in up-regulation of GW182 and Argonaute-2Aarti Jagannath, Matthew J A Wood
Science Translational Medicine|September 27, 2019
Wrangling RNA: Antisense oligonucleotides for neurological disordersKevin Talbot, Matthew J A Wood
Trends in Genetics : TIG|December 8, 2009
Therapeutic gene silencing strategies for polyglutamine disordersJanine Scholefield, Matthew J A Wood
Nature Reviews. Neurology|December 2, 2017
Antisense oligonucleotides: the next frontier for treatment of neurological disordersCarlo Rinaldi, Matthew J A Wood
Journal of Neuromuscular Diseases|June 7, 2021
Emerging Oligonucleotide Therapeutics for Rare Neuromuscular DiseasesYoshitsugu Aoki, Matthew J A Wood
Med (New York, N.Y.)|November 12, 2022
RNase-H-mediated silencing in the CNS proves predictably nontrivialMichael P Moazami, Matthew J A Wood
Pageof 20

Showing results (1-10 of 193) with videos related to

Sort By:
Pageof 20
Science Translational Medicine|April 29, 2010
Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challengeMatthew J A Wood
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 10, 2013
To skip or not to skip: that is the question for duchenne muscular dystrophyMatthew J A Wood
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|September 21, 2011
Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriersSamira Lakhal, Matthew J A Wood
Nature Reviews. Drug Discovery|August 2, 2011
Targeting RNA to treat neuromuscular diseaseFrancesco Muntoni, Matthew J A Wood
Molecular Biology of the Cell|October 24, 2008
Localization of double-stranded small interfering RNA to cytoplasmic processing bodies is Ago2 dependent and results in up-regulation of GW182 and Argonaute-2Aarti Jagannath, Matthew J A Wood
Science Translational Medicine|September 27, 2019
Wrangling RNA: Antisense oligonucleotides for neurological disordersKevin Talbot, Matthew J A Wood
Trends in Genetics : TIG|December 8, 2009
Therapeutic gene silencing strategies for polyglutamine disordersJanine Scholefield, Matthew J A Wood
Nature Reviews. Neurology|December 2, 2017
Antisense oligonucleotides: the next frontier for treatment of neurological disordersCarlo Rinaldi, Matthew J A Wood
Journal of Neuromuscular Diseases|June 7, 2021
Emerging Oligonucleotide Therapeutics for Rare Neuromuscular DiseasesYoshitsugu Aoki, Matthew J A Wood
Med (New York, N.Y.)|November 12, 2022
RNase-H-mediated silencing in the CNS proves predictably nontrivialMichael P Moazami, Matthew J A Wood
Pageof 20